Showing results (11-20 of 17) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Advances in Therapy|September 11, 2024
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02Ana Oaknin, Jung-Yun Lee, Vicky Makker, et al.Journal of Gynecologic Oncology|May 15, 2026
Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analysesJung-Yun Lee, Ana Oaknin, Luis Manso, et al.Advances in Therapy|March 6, 2025
Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02Ana Oaknin, Jung-Yun Lee, Vicky Makker, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2023
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II TrialFunda Meric-Bernstam, Vicky Makker, Ana Oaknin, et al.Blood|July 13, 2014
Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphomaPaul M Barr, Thomas P Miller, Jonathan W Friedberg, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2018
Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell LymphomaKevin R Kelly, Jonathan W Friedberg, Steven I Park, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2017
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin LymphomaMatthew S Davids, Andrew W Roberts, John F Seymour, et al.Pageof 2